Entero Therapeutics, Inc. announced on August 14, 2025, that it will effect a 1-for-3 reverse stock split of its common stock. The split is expected to commence trading on a split-adjusted basis on the Nasdaq Capital Market as of August 18, 2025.
This action was approved by the Board of Directors and shareholders and is being implemented to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing.
The reverse stock split will combine every three shares of the company's issued and outstanding common stock into one share, reducing the total outstanding shares from approximately 4.77 million to approximately 1.59 million shares.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.